Eli Lilly Dealmaking Profile 2007 - an in-Depth Insight into the Dealmaking Activity and Interests of One of the World's Leading Biopharma Companies

Business Wire, Sept 4, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c67364) has announced the addition of Eli Lilly Dealmaking Profile 2007 to their offering.

Each Company Dealmaking Profile provides an in-depth insight into the dealmaking activity and interests of one of the worlds leading biopharma companies.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

Key benefits

- Get ahead of your competitors by understanding and contacting the best partners of choice

- Identify prospective partner companies by analyzing their dealmaking activity and interests

- Undertake initial due diligence to assess suitability of partner companies

- Make direct contact with named business development executives within the company

- Review actual contract agreements entered into by the company and its partner companies

- Understand the key deal terms the company has agreed in previous deals

Report scope

Company Dealmaking Profiles are intended to provide business development executives, senior management and investors with decision-critical intelligence on a prospective partner's activities, interests and actual agreement contracts as signed by the company and its partners.

Each Company Dealmaking Profile includes:

- Company contact details - named contacts with their direct contact information

- Subsidiary companies

- Primary therapy areas

- Business development contacts

- Company description

- Marketed therapeutic indications

- Pipeline (phase I-III) therapeutic indications

- Partnering interests

- Partnering interests - therapeutic indications

- Partnering frequency per annum - 2000-2006

- Current partner companies (2005-6)

- Recent deals 2005-2006

? By deal type

? By stage of development

? By therapy area

- Contract documents available online 2005-2006 - link direct to each document

- What is actually granted by the agreement to the partner company?

- What exclusivity is granted?

- What is the payment structure for the deal?

- How are sales and payments audited?

- What is the deal term?

- How are the key terms of the agreement defined?

- How are IPRs handled and owned?

- Who is responsible for commercialization?

- Who is responsible for development, supply, and manufacture?

- How is confidentiality and publication managed?

- How are disputes to be resolved?

- Under what conditions can the deal be terminated?

- What happens when there is a change of ownership?

- What sublicensing and subscontracting provisions have been agreed?

- Which boilerplate clauses does the company insist upon?

- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

- Which jurisdiction does the company insist upon for agreement law?

Report breakdown

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Bigpharma - The Top 50

Chapter 3 - Most active bigpharma dealmakers

Chapter 4 - Top bigpharma deals - 2000-6

Chapter 5 - Company Profile

Chapter 6 - Resources

For more information visit http://www.researchandmarkets.com/reports/c67364